Matthew Williams

List of Publications by Year in Descending Order

40 papers	3,880 citations	25 h-index	42 g-index
42 ext. papers	4,246 ext. citations	13.5 avg, IF	5.37 L-index

#	Paper	IF	Citations
40	Inhibition of SHP-1 Expands the Repertoire of Antitumor T Cells Available to Respond to Immune Checkpoint Blockade. *Cancer Immunology Research*, **2020**, 8, 506-517	12.5	9
39	IL-10 Deficiency Reveals a Role for TLR2-Dependent Bystander Activation of T Cells in Lyme Arthritis. *Journal of Immunology*, **2018**, 200, 1457-1470	5.3	22
38	IFN-Gamma-Dependent and Independent Mechanisms of CD4+ Memory T Cell-Mediated Protection from Listeria Infection. *Pathogens*, **2018**, 7,	4.5	4
37	TCR signal strength controls the differentiation of CD4 effector and memory T cells. *Science Immunology*, **2018**, 3,	28	64
36	Inhibition of RON kinase potentiates anti-CTLA-4 immunotherapy to shrink breast tumors and prevent metastatic outgrowth. *OncoImmunology*, **2018**, 7, e1480286	7.2	14
35	Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade. *Journal of Biological Chemistry*, **2017**, 292, 18530-18541	5.4	54
34	A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma. *Oncotarget*, **2016**, 7, 64390-64399	3.3	48
33	Oct1 and OCA-B are selectively required for CD4 memory T cell function. *Journal of Experimental Medicine*, **2015**, 212, 2115-31	16.6	31
32	miR-155 promotes T follicular helper cell accumulation during chronic, low-grade inflammation. *Immunity*, **2014**, 41, 605-19	32.3	121
31	Dynamic functional modulation of CD4+ T cell recall responses is dependent on the inflammatory environment of the secondary stimulus. *PLoS Pathogens*, **2014**, 10, e1004137	7.6	10
30	Instant recall: a key role for effector-phenotype CD8+ memory T cells in immune protection. *Immunity*, **2013**, 38, 1090-1	32.3	5
29	Sustained interactions between T cell receptors and antigens promote the differentiation of CD4+ memory T cells. *Immunity*, **2013**, 39, 508-20	32.3	55
28	Inhibition of ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity. *Cancer Discovery*, **2013**, 3, 751-60	24.4	57
27	Disparate roles for STAT5 in primary and secondary CTL responses. *Journal of Immunology*, **2013**, 190, 3390-8	5.3	7
26	Antigen experience shapes phenotype and function of memory Th1 cells. *PLoS ONE*, **2013**, 8, e65234	3.7	9
25	Bim mediates the elimination of functionally unfit Th1 responders from the memory pool. *PLoS ONE*, **2013**, 8, e67363	3.7	7
24	Stability and function of secondary Th1 memory cells are dependent on the nature of the secondary stimulus. *Journal of Immunology*, **2012**, 189, 2348-55	5.3	12

23	Oct1 is a switchable, bipotential stabilizer of repressed and inducible transcriptional states. *Journal of Biological Chemistry*, **2011**, 286, 450-9	5.4	47
22	Nature and nurture: T-cell receptor-dependent and T-cell receptor-independent differentiation cues in the selection of the memory T-cell pool. *Immunology*, **2010**, 131, 310-7	7.8	27
21	Distinct roles for IL-2 and IL-15 in the differentiation and survival of CD8+ effector and memory T cells. *Journal of Immunology*, **2010**, 184, 6719-30	5.3	80
20	An activation marker finds a function. *Immunity*, **2010**, 32, 9-11	32.3	11
19	The magnitude of CD4+ T cell recall responses is controlled by the duration of the secondary stimulus. *Journal of Immunology*, **2009**, 183, 2382-9	5.3	33
18	Rapid culling of the CD4+ T cell repertoire in the transition from effector to memory. *Immunity*, **2008**, 28, 533-45	32.3	148
17	Effector and memory CTL differentiation. *Annual Review of Immunology*, **2007**, 25, 171-92	34.7	665
16	Requirements for CD8 T-cell priming, memory generation and maintenance. *Current Opinion in Immunology*, **2007**, 19, 315-9	7.8	116
15	Fully MHC-disparate mixed hemopoietic chimeras show specific defects in the control of chronic viral infections. *Journal of Immunology*, **2007**, 179, 2616-26	5.3	11
14	Developing and maintaining protective CD8+ memory T cells. *Immunological Reviews*, **2006**, 211, 146-53	11.3	125
13	Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. *Nature*, **2006**, 441, 890-3	50.4	604
12	Cutting edge: a single MHC class Ia is sufficient for CD8 memory T cell differentiation. *Journal of Immunology*, **2005**, 175, 2066-9	5.3	18
11	CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. *Nature Immunology*, **2004**, 5, 927-33	19.1	540
10	Conventional immunosuppression is compatible with costimulation blockade-based, mixed chimerism tolerance induction. *American Journal of Transplantation*, **2003**, 3, 895-901	8.7	20
9	Primary and secondary immunocompetence in mixed allogeneic chimeras. *Journal of Immunology*, **2003**, 170, 2382-9	5.3	25
8	Heterologous immunity provides a potent barrier to transplantation tolerance. *Journal of Clinical Investigation*, **2003**, 111, 1887-95	15.9	239
7	The role of the IL-2 pathway in costimulation blockade-resistant rejection of allografts. *Journal of Immunology*, **2002**, 168, 1123-30	5.3	49
6	Cutting edge: persistent viral infection prevents tolerance induction and escapes immune control following CD28/CD40 blockade-based regimen. *Journal of Immunology*, **2002**, 169, 5387-91	5.3	92

5	Dynamic regulation of T cell immunity by CD43. *Journal of Immunology*, **2002**, 168, 6022-31	5.3	90
4	Prevention of chronic rejection in murine cardiac allografts: a comparison of chimerism- and nonchimerism-inducing costimulation blockade-based tolerance induction regimens. *Journal of Immunology*, **2002**, 169, 2677-84	5.3	51
3	Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression. *Journal of Immunology*, **2001**, 167, 1103-11	5.3	139
2	Characterization of virus-mediated inhibition of mixed chimerism and allospecific tolerance. *Journal of Immunology*, **2001**, 167, 4987-95	5.3	83
1	Genetic characterization of strain differences in the ability to mediate CD40/CD28-independent rejection of skin allografts. *Journal of Immunology*, **2000**, 165, 6849-57	5.3	120